| __timestamp | Grifols, S.A. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 91733000 |
| Thursday, January 1, 2015 | 736435000 | 87644000 |
| Friday, January 1, 2016 | 775266000 | 92365000 |
| Sunday, January 1, 2017 | 860348000 | 85656000 |
| Monday, January 1, 2018 | 814775000 | 88196000 |
| Tuesday, January 1, 2019 | 942821000 | 89971000 |
| Wednesday, January 1, 2020 | 985616000 | 93413000 |
| Friday, January 1, 2021 | 1061508000 | 91355000 |
| Saturday, January 1, 2022 | 1190423000 | 113676000 |
| Sunday, January 1, 2023 | 1254234000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Grifols, S.A. and Taro Pharmaceutical Industries Ltd., from 2014 to 2023. Over this period, Grifols, S.A. consistently reported higher SG&A expenses, peaking in 2023 with a 90% increase from 2014. In contrast, Taro Pharmaceutical's SG&A expenses grew more modestly, with a notable 116% rise in 2023 compared to 2014. This disparity highlights Grifols' aggressive expansion and operational strategies, while Taro's steadier growth reflects a more conservative approach. The data for 2024 is incomplete, indicating potential shifts in strategy or reporting. Understanding these trends provides valuable insights into the financial health and strategic priorities of these pharmaceutical giants.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Grifols, S.A.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Taro Pharmaceutical Industries Ltd.
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Grifols, S.A. vs Ultragenyx Pharmaceutical Inc.
Annual Revenue Comparison: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?